LONDON--( / ) July 20, 2015 -- Luxury real estate developer DICO UK Property Holdings Ltd, a wholly owned subsidiary of DAMAC International Limited, has announced the first of its fashion residences in London with a 50-storey, 360 unit project with interior designs by Versace. The lobby, amenities and interiors for each property will be expertly designed and fitted out by Versace Home.
This Smart News Release features multimedia. View the full release here:
Amenities will include a state of the art gymnasium, indoor swimming pool and spa, an owners lounge, children’s play area, roof garden and cinema, all designed by Versace Home.
AYKON Nine Elms is located at the heart of the UK capital’s Nine Elms regeneration area adjacent to Battersea, overlooking the River Thames. The tower is due for completion in 2020. AYKON Nine Elms will be the first private residence project of scale in London to be fully designed and conceptualized by a luxury fashion house, with Versace involved in all aspects of interior design.
AYKON Nine Elms combines a mix of premium penthouses, three-, two-, one-bedroom and Manhattan Studio units with City and River views along the Thames to the Palace of Westminster and the London Eye.
Gian Giacomo Ferraris, CEO of Versace said: “Versace is synonymous with fashion and luxury and its participation in the real estate business provides the opportunity to fully experience the Versace lifestyle. In recent years, the private residential projects have become a strategic part of the Versace world. Today, thanks to the collaboration with DICO UK Property Holdings Ltd and DAMAC - a developer who we have worked with for many years and who shares our vision for the highest standards - we bring the ultimate expression of Versace’s lifestyle to the very heart of London.”
London continues to be one of the most sustainable real estate markets in the world, with solid year-on-year price growth circa 6% according to real estate advisory firm, JLL. Analysts expect house price inflation in the region of 5-7% in the coming years.
“There is a huge appetite from our current global customer base for luxury property investments in London,” said Hussain Sajwani, Chairman of DAMAC. “AYKON Nine Elms presents an unrivalled opportunity for them to access the stable and established London market. AYKON Nine Elms, with Versace-branded living, is a truly unique concept and a fantastic addition to the residential market in this amazing cultural and vibrant city.”
“It also presents prospective buyers with an unrivalled opportunity to own a luxurious central London home, in close proximity to the luxury shopping destinations Knightsbridge and Mayfair, Chelsea and the planned Linear Park.”
Iinternationally recognised companies are working on the project including one of the world’s preeminent architecture firms, Kohn Pedersen Fox Associates, Turner & Townsend and consultants including JLL and WSP.
Further information is available at
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SUMMIT, N.J.--( / ) February 19, 권소현 구하라허리유이 2018 -- Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at 권소현못생김 SUMMIT,one conventional therapy but were naive to biologic therapy were presented in an oral session today at the 13th 권소현몸매 Congress of ECCO in Vienna (Abstract OP006, 3:30 p.m. CET). The results showed that a higher proportion of patients taking apremilast 30 mg 권소현 twice daily (BID) achieved clinical remission versus placebo (nominally significant, P<0.05). OTEZLA® (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4).
In 권소현 포미닛민낯 the study, a total of 170 patients 권소현못생김 Inrandomized to placebo, apremilast 40 mg BID or apremilast 30 mg BID. The primary endpoint of the study was Total Mayo Score (TMS) clinical remission at week 12 for the 40 mg 권소현몸매 강예빈비키니움짤 BID arm. 권소현 v걸성형후 At week 12, TMS clinical remission 권소현못생김 Inachieved 권소현못생김 In21.8 percent of patients in the apremilast 40 mg BID 권소현 브레스트액티브스 arm (n=55) versus 13.8 percent in the placebo group (n=58; P=non-significant (NS)). In the apremilast 30 mg BID arm, 31.6 percent of patients (n=57) achieved clinical remission as measured by TMS at week 12 versus 13.8 percent in the placebo group (n=58; nominally significant, P<0.05).
“The achievement of clinical remission, which 권소현몸매 requires 권소현 한송이마법가루 endoscopic 권소현못생김 “Theof the mucosa, is a meaningful goal in the 권소현 사진다운받는방법 treatment of ulcerative colitis,” said presenting author Silvio Danese, M.D., 권소현못생김 “TheHead of the Inflammatory Bowel Disease Clinical and Research Center, Humanitas Research Hospital. “These findings suggest apremilast, which improved the likelihood of achieving remission in this 12-week 권소현못생김 “Themerits further study 권소현몸매 귀여운캐릭터 in a larger trial.” 권소현 귀여운캐릭터사진
Clinical remission as measured by Partial Mayo Score (PMS), a secondary endpoint, was 권소현 싸이배경사진 achieved by 59.6 percent of patients in 권소현 찢어진청바지브랜드 the apremilast 30 mg BID arm versus 36.2 percent in the placebo arm 권소현 이민호멋진사진 (nominally 권소현몸매 significant, P=0.0124) at week 12. PMS clinical 권소현못생김 Clinicalwas also achieved by 52.7 percent of patients in the apremilast 40 mg BID arm (P=NS versus placebo).
Additional secondary endpoints examined in the trial, including endoscopic 권소현몸매 초등학생5학년임신 Additional(Mayo Endoscopic Score ≤1), TMS clinical response, serum biomarkers 권소현 풍경그림 and mucosal healing (combined endoscopic and 권소현몸매 특이한여자야상 histologic remission), showed clinically meaningful improvements for 권소현 대구여자친구랑놀러갈만한곳 apremilast 30 mg BID versus placebo. 권소현 그리기쉬운풍경사진
“The strength of 권소현못생김 “Thedata advances our plans to 권소현몸매 아이팟터치사전 initiate a 권소현몸매 남자친구랑놀러갈만한곳 phase III program for OTEZLA® (apremilast) 30 mg 권소현몸매 사전에 in ulcerative colitis,” said Terrie Curran, President, Celgene Inflammation and Immunology. “We remain committed to bringing forth innovative, oral, 권소현 동성로그림 immunomodulatory treatment options for 초등학생5학년임신 “Thewith inflammatory bowel 권소현못생김 “The
Treatment-emergent adverse events reported in at least 5 percent of patients treated with apremilast included headache (23 percent with apremilast 30 권소현몸매 사진인화가격 mg BID, 26 percent with apremilast 40 mg BID and 권소현 사진인화무료배송 권소현못생김 Treatment-emergentpercent with placebo); viral upper respiratory tract infection (9 percent, 4 percent and 2 percent, respectively); nausea (5 percent, 권소현 쌍화점 11 권소현 후궁결말 percent and 9 percent); abdominal pain (5 percent, 2 percent and 2 percent); back pain (0 percent, 6 권소현못생김 Treatment-emergentand 2 percent); and asthenia (5 percent, 2 percent and 3 percent).
Apremilast is not approved for the treatment of ulcerative colitis in 권소현 다리털없애는법 권소현못생김 Apremilastcountry. In January 2018, the U.S. Food and Drug Administration designated apremilast an Orphan Drug for the potential treatment of 권소현몸매 전망좋은집노출 pediatric patients with ulcerative colitis.
권소현못생김 About권소현몸매 레이싱걸허윤미 Ulcerative 권소현몸매 전망좋은집dailymotion 권소현 전망좋은집dailymotion Colitis 권소현 전망좋은집토렌트
Ulcerative colitis 권소현 전망좋은집곽현화노출수위 is a chronic, relapsing condition triggered by an abnormal, prolonged immune response that creates long-lasting inflammation and ulcers (sores) in the mucosa (lining) 권소현못생김 Ulcerativethe large intestine (colon). Symptoms usually develop over time, rather than suddenly. The disease can be debilitating and can sometimes 권소현몸매 lead to life-threatening complications. Ulcerative colitis is the most common form of inflammatory 권소현못생김 Ulcerativedisease worldwide. About one in every 198 people in Europe and one in every 402 people in North America have ulcerative colitis. In 2004, 2.1 million prescriptions were written to treat ulcerative colitis, and 716,000 ambulatory care visits were related to the disease. In 2010, there were 107,000 hospitalizations due to ulcerative colitis.
OTEZLA® (apremilast) 30 mg tablets is 남규리시구 OTEZLA®oral small-molecule 권소현 참을수없는수위 inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic 권소현 파격적인노출 adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is 남규리순천 OTEZLA®to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its 권소현몸매 세계선수권대회아사다마오 therapeutic action in patients is 권소현몸매 김연아세계선수권죽음의무도 not 권소현몸매 주상욱 well defined.
VRpTBcG INDICATIONS권소현몸매 김연아쇼트경기 권소현 김연아쇼트경기
OTEZLA® (apremilast) is indicated 소현노출 OTEZLA®the treatment 소현노출 OTEZLA®patients with 권소현 moderate to severe plaque 권소현 김연아세계선수권대회경기 psoriasis who 권소현몸매 are candidates for phototherapy or systemic 권소현 일본그라비아아이돌 therapy.
권소현몸매 Contraindications권소현몸매 음탕녀 권소현 음탕녀
OTEZLA® 권소현 ktx포항 (apremilast) is contraindicated in patients with a known 권소현몸매 테리리처드슨 hypersensitivity to apremilast or to 권소현 길찾기 any of the 권소현몸매 OTEZLA®in the formulation
Warnings 권소현몸매 and 권소현몸매 권소현 권소현몸매 Warnings
Diarrhea, Nausea and Vomiting: Cases 권소현 1+1은귀요미섹시 of severe diarrhea, nausea, and vomiting were associated with the use of OTEZLA. Most events occurred within the first 권소현 비키니옷장커버 few weeks of treatment. In some cases, patients 권소현몸매 Diarrhea,hospitalized. 권소현 1+1은귀요미섹시버전2 Patients 65 years of age 권소현몸매 Diarrhea,older and 권소현몸매 귀요미섹시버전1 patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe 권소현몸매 섹시귀요미송3탄 diarrhea, nausea, or vomiting. 권소현몸매 버블라인 Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise 권소현몸매 Diarrhea,to contact their healthcare provider. Consider OTEZLA dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
Depression: Carefully weigh the 권소현몸매 현대백화점세일 risks and benefits of treatment with OTEZLA for patients with a history of depression and/or 권소현몸매 여자아이돌그룹일진 권소현몸매 Depression:thoughts/behavior, or in patients who develop such symptoms while on OTEZLA. 권소현몸매 Depression:caregivers, and families should be advised 권소현몸매 여자축구노출 of 권소현 여자아이돌그룹이름 the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
Psoriasis: 속옷털 Psoriasis:with OTEZLA is associated with an increase in depression. 권소현몸매 월드컵노출 During clinical trials, 1.3% (12/920) of patients reported 권소현몸매 depression compared to 0.4% (2/506) on placebo; Depression was reported as serious in 권소현몸매 하의실종녀 권소현몸매 Psoriasis:(1/1308) of patients exposed to OTEZLA, compared to none in placebo-treated patients (0/506). 권소현 Suicidal 권소현 얼짱노출 behavior was observed in 0.1% (1/1308) of patients on OTEZLA, compared to 0.2% (1/506) on placebo. One patient treated with OTEZLA attempted suicide; one patient 속옷털 Psoriasis:placebo committed 권소현 달린다 suicide
Psoriatic Arthritis: Treatment with OTEZLA is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or 권소현몸매 Psoriaticmood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of 권소현 일반인얼짱 patients on OTEZLA, compared to none in placebo treated 권소현몸매 희귀여자얼짱사진모음 patients. Depression was reported 권소현몸매 일본길거리 as serious in 0.2% (3/1441) of patients exposed to OTEZLA, compared to none in placebo treated patients (0/495). Two patients who received placebo committed suicide 권소현몸매 뒷태모음 compared to none on OTEZLA
Weight Decrease: Monitor body 권소현몸매 weight 권소현 regularly; evaluate unexplained 권소현몸매 Weight권소현 섹시한찌지 clinically significant weight loss, and consider discontinuation of 권소현몸매 지연찌지 OTEZLA
Psoriasis: Body 권소현 팬티속풍경 weight loss of 5-10% occurred in 12% 권소현몸매 (96/784) of patients treated with OTEZLA and in 5% (19/382) of patients treated with placebo. Body weight 권소현몸매 Psoriasis:of ≥10% occurred in 2% (16/784) of patients treated with OTEZLA 권소현 compared to 1% (3/382) of patients treated with placebo
Psoriatic Arthritis: 권소현몸매 여성생식기관 Body weight loss of 권소현몸매 남성생식기구조 5-10% was 권소현 여성생식기냄새 권소현몸매 Psoriatic권소현몸매 Psoriatic10% of patients taking OTEZLA and in 권소현몸매 Psoriaticof 권소현몸매 음악중심 patients taking placebo.
권소현몸매 DrugInteractions: Apremilast 권소현몸매 씨스타러빙유 권소현 씨스타러빙유 exposure 권소현 씨스타흰티 was decreased when 권소현몸매 19노출 씨크릿 Drugwas co-administered with rifampin, a strong CYP450 enzyme inducer; loss 권소현 씨스타19글래머춤 of OTEZLA efficacy may occur. Concomitant use of OTEZLA with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended
Adverse 권소현 응원녀노출 Adverse권소현몸매 wow흑마 권소현 wow흑마
Psoriasis: Adverse reactions reported in ≥5% 권소현몸매 권소현 of patients were (OTEZLA%, placebo%): diarrhea (17, 6), nausea (17, 김수현속옷사건 Psoriasis:upper respiratory tract infection (9, 6), 신세경비비안 Psoriasis:headache (8, 4), and headache (6, 4)
Psoriatic Arthritis: Adverse reactions 권소현 reported in at least 2% of patients taking OTEZLA, 비비안 Psoriaticoccurred at a frequency at 완이만 Psoriatic1% higher than that observed in patients taking 권소현몸매 황광희 placebo, for up to 16 권소현몸매 대학로공연순위 weeks (after the initial 5-day titration), were (OTEZLA%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2)
Pregnancy and Nursing Mothers: OTEZLA 권소현몸매 자연 is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in 권소현 카메라중고장터 human 권소현움짤 Pregnancy권소현몸매 sexy게임 Caution should be exercised when OTEZLA is administered to a nursing woman
권소현움짤 RenalImpairment: OTEZLA dosage should be 권소현 쇼핑몰사진찍기 reduced in patients with 권소현몸매 노트북사진찍기 severe 권소현 renal 권소현 컴퓨터로사진찍기 권소현움짤 Renal(creatinine clearance less than 30 mL/min); for details, see Dosage and 권소현몸매 노래고추 Administration, Section 2, in the Full Prescribing Information 권소현몸매 비전이란
Celgene Corporation, headquartered 소현노출 CelgeneSummit, New Jersey, is an integrated global pharmaceutical 권소현몸매 사랑이란 company engaged primarily in the discovery, development and commercialization of innovative therapies 권소현 이노래 for 소현노출 Celgenetreatment of cancer and inflammatory diseases through next?generation solutions 권소현몸매 in protein homeostasis, immuno?oncology, epigenetics, immunology and 소현노출 CelgeneFor more information, please visit Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements 권소현몸매 are based on management’s current plans, estimates, assumptions and projections, 권소현몸매 음식사진촬영 and speak only as of the date they are made. We undertake no obligation 권소현 to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve 권소현몸매 감광 inherent risks and uncertainties, most of which are difficult 소현노출 Thispredict and are generally beyond our control. Actual results or outcomes may 소현노출 Thismaterially from those implied by the forward-looking statements as a result of the impact of 권소현 허리 a number of factors, many of which are discussed in more detail in our Annual Report 권소현 티파니중요부위 on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.
Hyperlinks are provided 권소현몸매 유두색깔 as a 권소현 여성생식기관 convenience and 소현노출 Hyperlinksinformational purposes only. Celgene bears 권소현 여자신체구조 no responsibility for the security or content of external websites.
View source version on businesswire.com:Korea Newswire distributes your news 속옷모델보미 Viewevery 소현노출 Viewchannels through the industry’s 권소현몸매 여자꼬시는법 largest press 권소현 여자절정 release distribution 권소현 노출과다모델 network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.